NGR1 treatment was found to enhance the expression of ER and Smurf2 and to limit the phosphorylation of Smad2/3, demonstrating beneficial mechanisms relevant to the treatment of DCM (Figure 9F). The gene discussed is SMAD2; the disease is familial dilated cardiomyopathy.